Updates are available Correction dated 2022-02-22

Article History

Received: 23 November 2021

Revised: 29 December 2021

Accepted: 30 December 2021

First Online: 10 January 2022

Change Date: 22 February 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00415-022-11019-9

Declarations

:

: AC–C has received grant from Instituto de Salud Carlos III, Spain; JR19/00007; AZ has received travel expenses for scientific meetings from Biogen-Idec and Novartis, speaking honoraria from Eisai and a study grant from Novartis; JR has received speaking honoraria and personal compensation for participating on Advisory Boards from Almirall, Bayer Schering Healthcare, Biogen-Idec, Genzyme; GA has received compensation for consulting services or participation in advisory boards from Sanofi, Merck and Roche; research support from Novartis; travel expenses for scientific meetings from Novartis, Roche, Stendhal and ECTRIMS; speaking honoraria from Sanofi and Merck; and is a member of the International Women in Multiple Sclerosis (iWiMS) network executive committee; SO has received compensation for consulting services from Biogen-Idec and Genzyme, and research support from Novartis; PT was an ECTRIMS clinical fellowship awardee in 2019–2020; has received travel expenses for scientific meetings from Roche; SC-R was an ECTRIMS clinical fellowship awardee 2019–2020; has received travel expenses for scientific meetings from Biogen-Idec and Genzyme; compensation for consulting services or participation in advisory boards from Roche and Novartis; and speaking honoraria from Novartis. MC reports no disclosures. CE reports no disclosures; MR reports no disclosures; PC has received travel expenses from Biogen. PC’s yearly salary is supported by a grant from Biogen to Fundació privada Cemcat towards statistical analysis; BR has received honoraria for consulting services from Wellspect; LM has received honoraria for consulting services and speaking honoraria from Roche and Novartis; AVJ has received compensation for consulting services and speaking honoraria from Novartis, Roche, Teva, Mylan, Biogen and Genzyme-Sanofi. CT is currently being funded by a Junior Leader La Caixa Fellowship. The fellowship code is LCF/BQ/PI20/11760008. She has also received the 2021 Fundación Merck Salud Award for the Investigation in Multiple Sclerosis (Spain). In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society; IG reports no disclosures; JC reports no disclosures; MC has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merck Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis and Novartis; CN has received funding for travel from Biogen-Idec and F. Hoffmann-La Roche, Ltd., and speaker honoraria from Novartis; CA reports no disclosures; MT is co-editor of Multiple Sclerosis Journal-Experimental, Translational and Clinical, and has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis Viela-Bio and Teva Pharmaceuticals AR serves/ed on scientific advisory boards for Novartis, Sanofi-Genzyme, Synthetic MR, Bayer, Roche, Biogen, Icometrix and OLEA Medical, and has received speaker honoraria from Bayer, Sanofi-Genzyme, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche and Biogen. XM has received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past 3 years with Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, Genzyme, Immunic, Medday, Merck, Mylan, Nervgen, Novartis, Roche, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS; JS-G has received compensation for consulting services and speaking honoraria from Almirall, Bayer, Biogen, Celgene, Sanofi, Merck, Novartis, Roche, Bial, Biopass and Teva, is member of the editorial committee of Multiple Sclerosis Journal, and director of Humoral and cellular responses to SARS-CoV-2 in convalescent COVID-19 patients with Multiple Sclerosis Revista de Neurología M.

: The study was approved in the session Number 499 by the local Ethics Committee at Vall d’Hebron University Hospital (VHUH) in Barcelona, Spain.

: Written informed consent for participation was not required for this study.

Free to read: This content has been made available to all.